Petros Pharmaceuticals, Inc.
PTPI
$0.01
$0.0029.03%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 725.40K | 2.30M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 725.40K | 2.30M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.40M | 4.21M | 4.64M | 4.83M | 5.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.40M | 4.21M | 4.64M | 4.83M | 5.03M |
| Operating Income | -3.40M | -4.21M | -4.64M | -4.83M | -5.03M |
| Income Before Tax | -3.20M | -4.29M | -4.50M | -4.72M | -4.71M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.20 | -4.29 | -4.50 | -4.72 | -4.71 |
| Earnings from Discontinued Operations | 0.00 | 7.47M | 6.41M | -2.31M | -3.61M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.20M | 3.19M | 1.91M | -7.02M | -8.32M |
| EBIT | -3.40M | -4.21M | -4.64M | -4.83M | -5.03M |
| EBITDA | 33.40K | -1.06M | -1.81M | -2.05M | -2.22M |
| EPS Basic | -0.31 | -1.21 | -10.56 | -37.28 | -50.60 |
| Normalized Basic EPS | -0.04 | -0.08 | -0.71 | -1.56 | -3.01 |
| EPS Diluted | -0.31 | -1.21 | -10.56 | -37.28 | -50.60 |
| Normalized Diluted EPS | -0.04 | -0.08 | -0.71 | -1.56 | -3.01 |
| Average Basic Shares Outstanding | 178.34M | 156.87M | 111.81M | 69.77M | 27.88M |
| Average Diluted Shares Outstanding | 178.34M | 156.87M | 111.81M | 69.77M | 27.88M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |